AbbVie Inc. (ABBV) vs ASML Holding N.V. (ASML)
See how AbbVie Inc. and ASML Holding N.V. differ across market data and performance, so you can decide which asset best fits your strategy.
$256.42
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
View Full Page$1,696.01
NasdaqGS
Key Metrics Comparison
AbbVie Inc.ABBV
Market Cap$453.124B
Price$256.42
24h Change+0.37%
24h Volume$4.24M
Employees57,000
Shares Outstanding1,768,169,012
ASML Holding N.V.ASML
Market Cap$651.437B
Price$1,696.01
24h Change-0.01%
24h Volume$1.2M
Employees43,938
Shares OutstandingN/A
Category Performance
Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.
Market Share
Share of combined market cap
ABBV
41.0%ASML
59.0%Volume Share
Share of combined 24h volume
ABBV
78.0%ASML
22.0%24h Performance
Price change over last 24 hours
ABBV
0.37%ASML
-0.01%Price Comparison
AbbVie Inc.
ASML Holding N.V.